Clinical Trials | Oncura Health

Research That Lives Where you Live

Breakthrough cancer care … delivered with compassion, right here close to home.

Through clinical research, we bring new possibilities to patients and families when they

need them most

Find out more about our clinical trials >>

When It Matters Most, Options Matter Most

When you’re facing cancer, every option matters. Every moment matters. Clinical research isn’t just about future medicine. It’s about expanding your options today.

At Oncura Health, clinical trials are part of the care we provide every day.

That means you may have access to:

Promising new treatments earlier
More personalized approaches to care
Additional options beyond standard therapy
Advanced care, without traveling far from home

Most people think clinical trials only happen at large academic hospitals.

At Oncura, they happen where you already receive care. Close to home, with a team you trust.

Learn More

Clinical Research Trials Available

Clinical trials may be available across a range of cancer types and conditions, including:

Breast Cancer (HR+ / HER2-)

CAPItello-292 — Phase Ib/III Clinical Trial
(CAPItello-292) A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer.

ClinicalTrials.gov

Breast Cancer (HR+ / HER2-)

CAMBRIA-2 — Phase III Clinical Trial

(CAMBRIA-2) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease.

ClinicalTrials.gov

Breast Cancer (HR+ / HER2-)

HERTHENA-Breast04 — Phase 3 Clinical Trial

(HERTHENA-Breast04) An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer.

ClinicalTrials.gov

Breast Cancer (HR+ / HER2-)

pionERA Breast Cancer — Phase III Clinical Trial
(pionERA Breast Cancer) A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy.

ClinicalTrials.gov

Breast Cancer (HR+ / HER2-)

Phase 1b/2 Study of Disitamab Vedotin
A Phase 1b/2, Open-Label, Multicohort Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer.

ClinicalTrials.gov

Breast Cancer (HR+ / HER2-)

Phase 3 Study of PF-07248144 Plus Fulvestrant
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy.

ClinicalTrials.gov

Breast Cancer (TNBC)

ASCENT-05 — Phase 3 Clinical Trial
(ASCENT-05) A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.

ClinicalTrials.gov

Breast Cancer (TNBC)

TROPION-Breast05 — Phase III Clinical Trial
(TROPION-Breast05) A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer.

ClinicalTrials.gov

Breast Cancer (TNBC)

Phase 1/2 Study of Sacituzumab Govitecan at an Alternative Dose and Schedule
A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer.

ClinicalTrials.gov

Breast Cancer (HER2+)

EmpowHER-303 — Phase 3 Clinical Trial
(EmpowHER-303) A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment.

ClinicalTrials.gov

Breast Cancer (HER2+)• Breast Cancer (HR+ / HER2-)• Breast Cancer (TNBC)

BRIA-ABC — Phase 3 Clinical Trial
(BRIA-ABC) Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer

ClinicalTrials.gov

Colorectal Cancer (CRC)

ClinicalTrials.gov

(HARMONi-GI3) A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer

Colorectal Cancer (CRC)

ClinicalTrials.gov

(MOUNTAINEER-03) An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer

Colorectal Cancer (CRC)

ClinicalTrials.gov

(OrigAMI-2) A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Colorectal Cancer (CRC)

ClinicalTrials.gov

(OrigAMI-3) A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Essential Thrombocythemia (ET)

Clinical Trials.gov

(MK-3543-006) A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea

Essential Thrombocythemia (ET)

Clinical Trials.gov

(MK-3543-007) A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants

Gastric (Stomach) Cancer• Gastroesophageal Junction Cancer (GEJ)

A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer

ClinicalTrials.gov

Lung Cancer (SCLC - Small Cell Lung Cancer)

ClinicalTrials.gov

(EVOKE-SCLC-04) A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Lung Cancer (NSCLC - Non-Small Cell Lung Cancer)

ClinicalTrials.gov

(ARTEMIDE-Lung02) A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

Lung Cancer (NSCLC - Non-Small Cell Lung Cancer)

ClinicalTrials.gov

(ARTEMIDE-Lung03) A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

Lung Cancer (NSCLC - Non-Small Cell Lung Cancer)

ClinicalTrials.gov

(COPERNICUS) A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Lung Cancer (NSCLC - Non-Small Cell Lung Cancer)

ClinicalTrials.gov

(DESTINY-Lung06) A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer

Lung Cancer (NSCLC - Non-Small Cell Lung Cancer)

ClinicalTrials.gov

(HARMONIC) Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors

Lung Cancer (NSCLC - Non-Small Cell Lung Cancer)

ClinicalTrials.gov

(HARMONi-3) A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer

Lung Cancer (NSCLC - Non-Small Cell Lung Cancer)

ClinicalTrials.gov

(HARMONi-7) A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression

Lung Cancer (NSCLC - Non-Small Cell Lung Cancer)

ClinicalTrials.gov

(TROPION-Lung10) A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Lung Cancer (NSCLC - Non-Small Cell Lung Cancer)

ClinicalTrials.gov

(TROPION-Lung14) A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer

Lung Cancer (NSCLC - Non-Small Cell Lung Cancer)

ClinicalTrials.gov

(TROPION-Lung15) A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment

Biliary Tract Cancer

DESTINY-BTC01 — Phase 3 Clinical Trial

A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First-Line Locally Advanced or Metastatic HER2-Expressing Biliary Tract Cancer.

ClinicalTrials.gov

Myelodysplastic Syndromes (MDS)

(ELEMENT-MDS) A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD)

Clinical Trials.gov

Other Solid Tumors (Basket Trial)

ClinicalTrials.gov

(IDeate-PanTumor02) A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors

Other Solid Tumors (Basket Trial)

ClinicalTrials.gov

Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers

What Patients Should Know

Clinical trials:

Follow strict safety, ethical, and regulatory guidelines

Allow patients to withdraw at any time

Our Research & OneOncology Partnership

As part of the OneOncology network, Oncura Health collaborates with leading research institutions and sponsors to support responsible clinical trial awareness and access.
This partnership helps:

Expand visibility into available research opportunities

Support coordinated care across participating practices

Advance innovation while preserving the physician–patient relationship

Patients are encouraged to discuss all treatment options with their physician before making decisions.

Interested in learning more about clinical trials or research opportunities?

Our team is here to help answer questions and support next steps.

Oncura Health provides education and care coordination related to clinical trials.
We do not provide medical advice or determine eligibility. All treatment decisions are made between patients and their physicians.

Oncura Heath provides education and care coordination related to clinical trials.

We do not provide medical advice or determine eligibility. All treatment decisions are made between patients and their physicians.